Research Article

Vitamin D-induced vitamin D receptor expression induces tamoxifen sensitivity in MCF-7 stem cells via suppression of Wnt/β-catenin signaling

Wei Zheng1, Bofeng Duan1, Qian Zhang2, Linna Ouyang1, Wei Peng1, Fuyong Qian1, Yibin Wang1 and Shiting Huang1

1Department of Breast and Thyroid Surgery, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong 518112, China; 2Teaching and Research Section of Surgery, Xiangnan University Affiliated Hospital, Chenzhou, Hunan 423000, China

Correspondence: Wei Zheng (SZTPHZhengwei@hotmail.com)

Objective: Cancer stem cells (CSCs) are responsible for the drug resistance of breast cancers. Vitamin D deficiency promotes tumor resistance. The present study examined the effect of vitamin D and vitamin D receptor (VDR) expression on the tamoxifen resistance of CSCs. Methods: MCF-7 cells were treated with 1,25(OH)2D3 and their levels of VDR expression, viability, and apoptosis were detected. CD133+ MCF-7 stem cells were identified and transfected with a VDR-overexpression plasmid. The tamoxifen concentration that reduced MCF-7 cell viability by 50% (IC50) was determined. The activation of Wnt/β-catenin signaling was also investigated. Results: Vitamin D reduced the viability of MCF-7 cells and promoted their apoptosis. Vitamin D enhanced VDR expression and induced DNA damage. When CD133+ stem cells were separated from MCF-7 cells, the IC50 of tamoxifen for stem cells was significantly higher than that of parental MCF-7 cells, suggesting a higher tamoxifen resistance in MCF-7 stem cells. Levels of VDR expression and Wnt/β-catenin signaling in CD133+ cells were markedly lower and higher than those in CD133− cells, respectively. Stem cells transfected with VDR overexpression plasmids showed decreased tamoxifen IC50 values, viability, spheroid formation, and expression of Wnt and β-catenin proteins when compared with control cells. Cell apoptosis was increased by transfection with a VDR overexpression plasmid. Finally, the inhibitory effects induced by VDR overexpression could be reversed by the VDR inhibitor, calcifediol. Conclusion: Stem cells contributed to the tamoxifen resistance of MCF-7 cells. Vitamin D-induced VDR expression increased the sensitivity of MCF-7 stem cells to tamoxifen by inhibiting Wnt/β-catenin signaling.

Introduction

Breast cancer is the second most common malignancy in women, and accounts for almost 30% of new cancers and 15% of cancer-related deaths [1,2]. Breast cancer is an malignancy with a poor prognosis because of its genetic and phenotypic diversity, delayed diagnosis, and resistance to radiation and chemotherapy [3].

Cancer stem cells (CSCs) comprise a small number of cells within tumors and have features similar to normal stem cells, such as embryonic stem cells [4,5]. It has been well documented that CSCs are responsible for the initiation, metastasis, and drug resistance of cancer cells [6–8]. CSCs from malignancies have been identified and reported to contribute to tumor metastasis and chemoradiotherapy resistance [9,10]. It is reported that breast cancer is driven by breast CSCs, which in turn drive tumor formation, metastasis.
and resistance to chemotherapy [9–11]. The persistent activation of some conserved signaling pathways in CSCs, including the Notch and Wnt signaling pathways, guarantees the continued development of breast tumors and their metastasis [5,12]. High levels of CSCs in breast cancer specimens are always predictive of metastasis, resistance to chemotherapeutic agents, and a poor clinical outcome [4,13,14].

Vitamin D deficiency is a common factor found in patients with many disorders, including breast cancer, and a low vitamin D level is advantageous for tumor development, drug resistance, and metastasis [1,15,16]. Women with sufficient supplementation of calcium and vitamin D showed a decreased risk for invasive breast cancers [17].

Vitamin D is not only a vitamin, but also a multifunctional pro-hormone and a precursor to calcitriol [1,25-dihydroxy-vitamin D3 (1,25(OH)2D3)], which is a potent steroid hormone [18]. The etiology of vitamin D deficiency-mediated cancers is characterized by an alteration in the oncogenic Wnt/β-catenin signaling pathway or the APC/β-catenin/TCF tumor suppressor pathway [5,19,20]. So et al. [21] found that administration of 1,25(OH)2D3 or its analogs decreased Notch ligand levels, inhibited Notch 1 signaling, and reduced the CSC numbers among breast cancer cells. There is increasing evidence showing that vitamin D may exert therapeutic effects in breast cancer patients by inhibiting certain signaling pathways found in CSCs. Moreover, the resistance of breast cancer to tamoxifen is mediated by CSCs [22].

The present study explored the effect of vitamin D on breast cancer cells, including their viability, apoptosis, and VDR expression. The influence of VDR expression on the tamoxifen resistance of MCF-7 stem cells will be discussed. The association between Wnt/β-catenin signaling and VDR-mediated tamoxifen resistance in MCF-7 stem cells was studied. Our study results provide new insights into the association of tamoxifen resistance in MCF-7 stem cells with VDR expression and Wnt/β-catenin signaling.

Materials and methods

Cell culture and vitamin D treatment

Human MCF-7 breast cancer cells were purchased from ATCC (Manassas, VA, U.S.A.). The cells were maintained and expanded in DMEM (Hyclone, Logan, UT, U.S.A.) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, U.S.A.) at 37 °C, in a 5% CO2 atmosphere. Cells were treated with 0, 0.001, and 0.1 μM 1,25(OH)2D3 at 37 °C with 5% CO2. Each cellular treatment was performed in triplicate. The VDR inhibitor calcifediol (S1469) was used at a concentration of 0.1 μM to block the VDR.

Fluorescence-activated cell sorting and CD133+ CSC treatment

CD133+ stem cells were separated from MCF-7 cells by use of fluorescence-activated cell sorting methods [23]. In brief, cells were centrifuged and labeled with a FITC-conjugated CD133 antibody (eBiosciences, San Diego, CA, U.S.A.) for 30 min; after which, they were sorted using a Becton Dickinson (BD) fluorescence-activated cell sorter (BD Biosciences, San Jose, CA, U.S.A.). Individual CD133+ stem cells were manually removed under a microscope and expanded in DMEM (Hyclone, Logan, UT, U.S.A.) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, U.S.A.) for 1 h; after which, they were sorted using a BD fluorescence-activated cell sorter (BD Biosciences, San Jose, CA, U.S.A.).

VDR expression plasmid construction and CSC transfection

The VDR-overexpression plasmid was constructed by cloning the full length VDR CDS sequence into a pcDNA3.0 expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene expression vector (GeneChem Co. Ltd., Shanghai, China).

So et al. [21] found that administration of 1,25(OH)2D3 or its analogs decreased Notch ligand levels, inhibited Notch 1 signaling, and reduced the CSC numbers among breast cancer cells. There is increasing evidence showing that vitamin D may exert therapeutic effects in breast cancer patients by inhibiting certain signaling pathways found in CSCs. Moreover, the resistance of breast cancer to tamoxifen is mediated by CSCs [22].

The present study explored the effect of vitamin D on breast cancer cells, including their viability, apoptosis, and VDR expression. The influence of VDR expression on the tamoxifen resistance of MCF-7 stem cells will be discussed. The association between Wnt/β-catenin signaling and VDR-mediated tamoxifen resistance in MCF-7 stem cells was studied. Our study results provide new insights into the association of tamoxifen resistance in MCF-7 stem cells with VDR expression and Wnt/β-catenin signaling.

Materials and methods

Cell culture and vitamin D treatment

Human MCF-7 breast cancer cells were purchased from ATCC (Manassas, VA, U.S.A.). The cells were maintained and expanded in DMEM (Hyclone, Logan, UT, U.S.A.) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, U.S.A.) at 37 °C, in a 5% CO2 atmosphere. Cells were treated with 0, 0.001, and 0.1 μM 1,25(OH)2D3 at 37 °C with 5% CO2. Each cellular treatment was performed in triplicate. The VDR inhibitor calcifediol (S1469) was used at a concentration of 0.1 μM to block the VDR.

Fluorescence-activated cell sorting and CD133+ CSC treatment

CD133+ stem cells were separated from MCF-7 cells by use of fluorescence-activated cell sorting methods [23]. In brief, cells were centrifuged and labeled with a FITC-conjugated CD133 antibody (eBiosciences, San Diego, CA, U.S.A.) for 30 min; after which, they were sorted using a Becton Dickinson (BD) fluorescence-activated cell sorter (BD Biosciences, San Jose, CA, U.S.A.). Individual CD133+ stem cells were manually removed under a microscope and maintained in serum-free DMEM/F-12 medium (Hyclone) that was supplemented with 2% B27 (Invitrogen, Life Technologies, Grand Island, NY, U.S.A.), 0.4% BSA (Sigma-Aldrich), 1% penicillin/streptomycin, bFGF, and EGF (20 ng/mL each, PeproTech, Inc., Rocky Hill, NJ, USA), insulin (10 μg/mL, Sigma-Aldrich), hydrocortisone (0.5 μg/mL, Invitrogen), and sodium glutamate (2 mM, Invitrogen) at 37 °C and 5% CO2 [24].

VDR expression plasmid construction and CSC transfection

The VDR-overexpression plasmid was constructed by cloning the full length VDR CDS sequence into a pcDNA3.0 expression vector (GeneChem Co. Ltd., Shanghai, China). The full length VDR gene CDS was obtained from MCF-7 cells by using the VDR forward primer (5′-GGGTACCATGGAGGCAATGGCGGC-3′) and reverse primer (5′-CCGCTCGAGTCAGGAGATCTCATTGCCAAACA-3′). The PCR products and pcDNA3.0 vectors were digested with KpnI (Thermo Fisher Scientific, Waltham, MA, U.S.A.) and Xhol (Thermo Fisher Scientific) at 37 °C for 2 h, and then ligated by incubation with T4 DNA Ligase (Thermo Fisher Scientific) at 22 °C for 2 h. The purified products (0.4 μg of plasmids) and empty vectors (negative controls) were used for transfection into CSCs (100 μL, 1 × 105/mL). The transfections were performed using 0.5 μL of Lipofectamine™ 2000 (Invitrogen) according to the manufacturer’s instructions. Cells were incubated in serum-free DMEM/F-12 (Hyclone) medium that was supplemented with the factors described above at 37 °C with 5% CO2 and then harvested at 48 h after cell transfection. All experiments were performed in triplicate.
**Spheroid SEM imaging**

An ultrastructure analysis of CSC spheroids was performed using SEM imaging. Aliquots of isolated single cells ($5 \times 10^4$) were seeded into 24-well agar-coated plates and cultured under the conditions described above for 7 days. After being treated with methods recently described by Boo et al. [24].

**Soft agar colony formation assay**

Soft agar colony formation was performed as described [24]. Briefly, a mixture, consisted by 1.2% agar solution, $2 \times$ DMEM medium and about 2000 cells, was immited into 96-well plate, and then plates were transfer into incubator for 10 days. Finally, plates were observed and photographed under microscope.

**Immunofluorescence assay**

Spheres derived from CD133+ CSCs were centrifuged on slides by using cytopsins according to recently described methods [6]. Next, cells were fixed and prepared with 0.1% Triton, blocked with BSA, and then incubated in solutions that contained FITC-conjugated CD33 antibody (1:500, eBiosciences); after which, they were incubated with an IgG-FITC fluorescent antibody (1:500, eBiosciences) and stained with DAPI. For DNA damage determination, Hoechst 33258 staining solution (Beyotime Institute of Biotechnology, Shanghai, China) was added into solutions that contained fixed cells and incubated for 30 min at room temperature. The cells were then examined under an Olympus confocal microscope (FV 1000, Olympus, Tokyo, Japan).

**Drug sensitivity assay**

The sensitivity of parental MCF-7 cells and separated CSCs (CD133+) to the chemotherapeutic drug tamoxifen was measured using the MTT assay (Sigma-Aldrich) [24]. MCF-7 cells and CD133+ CSC spheroids were placed into 96-well plates at the conditions described above. Spheroids in 3D format and 2D format, and monolayer cells were dissociated into single cells, filtered, and counted. Next, aliquots containing $5 \times 10^5$ cells were placed into the wells of culture plates that were supplemented with tamoxifen (0–32 $\mu$M) and incubated for 96 h. MTT solution was then added to each well (20 $\mu$l/well) and the cells were incubated for another 4 h prior to addition of DMSO (170 $\mu$l/well). The absorbance of cell cultures was detected using a microplate reader (Bio-Rad, Hercules, CA, U.S.A.). The percentage of viable cells and degree of cell cytotoxicity were determined by comparing the absorbance of treated cells with that of control cells (defined as 100%). Dose-response curves for the MCF-7 cells and CSCs were constructed, and the tamoxifen concentration that produced a 50% reduction in cell viability (IC$_{50}$) was calculated.

**Flow cytometric analysis**

For apoptosis analysis, single cells were seeded into the wells of 6-well plates ($5 \times 10^5$ cells/well) and incubated for 24 h; after which, 1,25(OH)$_2$D$_3$ was added and the cells were incubated for an additional 48 h. Next, the cells were harvested, digested to single cells using 0.25% trypsin (Gen-View Scientific, Inc., El Monte, FL, U.S.A.), and prepared for apoptosis detection that was performed after adding 200 $\mu$l of Annexin V/Propidium Iodide (PI) staining solution (BD Biosciences). For the EdU proliferation assay, cells in 96-well plates were first treated with 1,25(OH)$_2$D$_3$ for 48 h and then treated with 50 $\mu$M EdU solution for 2 h (100 $\mu$l/well, RiboBio, Guangzhou, Guangdong, China). The cells were then analyzed by flow cytometry as described in the manufacturer's instructions. All flow cytometric analyses were performed using a BD FACS Calibur™ flow cytometry (BD Biosciences).

**Western blot analysis**

Total cellular proteins were isolated from MCF-7 cells and CSC spheroids using lysis buffer (Beyotime). Samples of protein (35 $\mu$g) were separated by 10% SDS/PAGE (Sangon, Shanghai, China), and the separated protein bands were transferred onto PVDF membranes (Millipore, Whatman, Germany), which were then blocked with 5% skimmed milk (Beyotime). Next, the membranes were incubated with specific primary monoclonal antibodies against VDR (1:400, Abcam, Cambridge, U.K.), Wnt (1:1000, Abcam), β-catenin (1:5000, Abcam), and GAPDH (1:10,000, Abcam) at room temperature for 1 h. HRP Goat anti-Rabbit/mouse IgG (1:20,000, Boster Biotechnology Ltd., Wuhan, China) was used as the secondary antibody. The membranes were developed with an ECL system (Millipore, Billerica, MA, U.S.A.), and Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Bethesda, MD, U.S.A.) was used to determine the optical density of each protein blot.
Figure 1. Effect of vitamin D on cell proliferation and apoptosis
(A) EdU flow cytometric analysis. (B) Cell apoptosis analysis by flow cytometry. (C) Hoechst 33258 immunofluorescence assay; ×400 magnification. (D) Expression of the VDR protein in cells as determined by Western blot analysis. GAPDH was used as reference control. MCF-7 cells were treated with 0 μM (blank), 0.001 μM (low dose), or 0.1 μM 1,25(OH)2D3 (high dose) for 48 h before each examination. *, **, and *** denote P < 0.05, 0.01, and 0.001 compared with Blank cells, respectively.

Statistical analysis
All statistical analyses were performed using GraphPad Prism 6.0 software, and results are shown as the mean ± S.D. Student's t test was used to analyze differences, and P-values < 0.05 were considered statistically significant.

Results
Vitamin D treatment suppressed cell proliferation and induced cell apoptosis
MCF-7 cells treated with 1,25(OH)2D3 showed a dose-dependent increase in the percentage of apoptotic cells and a dose-dependent decrease in proliferation ability. When compared with the percentage of EdU+ cells among blank cells (51.9 ± 4.8%), the EdU+ percentages were significantly lower among MCF-7 cells treated with 0.001 μM (25.5 ± 4.8%) or 0.1 μM 1,25(OH)2D3 (7.5 ± 1.5%) (P < 0.01 and P < 0.001, respectively). Furthermore, the percentage of cells in G0/G1 phase was markedly increased and the percentage in G2/S phase was dramatically reduced (Figure 1A). In contrast, the percentages of apoptotic cells among cells treated with 0.001 μM (25.3 ± 0.9%) or 0.1 μM 1,25(OH)2D3 (40.2 ± 1.6%) were significantly higher than the percentage among blank control cells (7.6 ± 0.5%; P < 0.01 and P < 0.001, respectively; Figure 1B). Results of the Hoechst 33258 immunofluorescence assay confirmed that 1,25(OH)2D3 administration had indeed induced more aggregation or brilliant blue spots in cells, indicating that...
Figure 2. Characteristics of CSCs
(A) Spheroids identified by an immunofluorescence assay performed with FITC-conjugated CD133 antibodies; scale bar = 20 μm.
(B) The tamoxifen concentration that reduced the numbers of viable parental MCF-7 cells and CD133+ CSCs by 50% (IC50). (C, D),
expression of the VDR protein and Wnt/β-catenin signaling factors in CD133− and CD133+ cells derived from MCF-7 cells. Cells
were sorted using a fluorescence-activated cell sorting method. ** and **** denote P<0.01, and P=0.0001 compared with blank
cells, respectively.

DNA damage had occurred in a dose-dependent manner (Figure 1C). These results suggested that 1,25(OH)2D3 had
suppressed the proliferation ability of the MCR-7 cells and induced cell apoptosis by causing DNA damage.

Vitamin D administration enhanced VDR expression
Because proper function of the VDR requires the bioactivation of vitamin D, we detected the level of VDR protein
expression in response to vitamin D administration in MCF-7 cells. As expected, we detected an up-regulation of
VDR protein expression in the MCR-7 cells treated with 1,25(OH)2D3 (Figure 1D). These results indicated that ad-
ministration of 1,25(OH)2D3 to cultured MCF-7 cells indeed activated vitamin D-mediated metabolic processes.

MCF-7 stem cells showed a relatively higher resistance to tamoxifen
MCF-7 stem cells were sorted by using the CD133 antibody and fluorescence-activated cell sorting methods. MCF-7
stem cell spheroids were identified by using the FITC-conjugated CD133 antibody in an immunofluorescence assay
(Figure 2A). Next, we determined that the IC50 value of tamoxifen for MCF-7 CSCs (29.44 ± 0.33 μM) was signifi-
cantly higher than that for parental MCF-7 cells (5.74 ± 0.22 μM, P<0.0001; Figure 2B). These results suggested that
the stem cells had a higher resistance to tamoxifen.

VDR expression inactivated Wnt/β-catenin signaling
We next confirmed the presence of VDR expression, and found that VDR expression in CD133+ stem cells was lower
than that in CD133− cells (P<0.01, Figure 2C). However, the levels of Wnt and β-catenin protein expression in
CD133+ cells were higher than those in CD133− cells (P<0.01, Figure 2D), which was contrary to the trend shown
by the VDR. These results suggested that VDR expression blocked the Wnt/β-catenin signaling pathway, and CD133+
CSCs had a lower capacity for activating vitamin D-mediated metabolic processes. Additionally, the higher resistance
of CD133+ cells to tamoxifen might be mediated by the activation of Wnt/β-catenin signaling.

VDR mediates tamoxifen sensitivity in MCF-7 stem cells via the
inactivation of Wnt/β-catenin signaling
To investigate the association of VDR-mediated tamoxifen sensitivity with activation of Wnt/β-catenin signaling
in MCF-7 stem cells, we transfected CSCs with the VDR-overexpression plasmid, pc-VDR. We found up-regulated
levels of VDR expression in the transfected cells when compared with VDR expression in the blank cells and negative
controls (NC, transfected with pcDNA3.0 vectors, \( P < 0.05 \), Figure 3A). Next, we found that the IC\(_{50}\) value of tamoxifen for transfected cells (16.10 ± 1.13 \( \mu \)M) was lower than that for the controls (\( > 22 \mu \)M, \( P < 0.01 \), Figure 3B), suggesting that overexpression of the VDR had sensitized the CSCs to tamoxifen.

In addition, we found that VDR-overexpressing CSCs developed fewer and smaller spheroids (Figure 3C), were less viable (Figure 3D, \( P < 0.001 \)), and had higher apoptotic rates (Figure 3E, \( P < 0.01 \)) than the control cells (blank and NC). These results indicated that VDR expression enhanced CSC apoptosis and suppressed cell proliferation. Finally, we found that overexpression of the VDR inhibited Wnt and β-catenin protein expression in CSCs, suggesting that VDR expression suppresses Wnt/β-catenin signaling in MCF-7 stem cells. Our results also suggest that overexpression of the VDR in MCF-7 stem cells might sensitize stem cells to tamoxifen by promoting cell apoptosis via the inactivation of Wnt/β-catenin signaling.

**A VDR inhibitor reversed the inhibitory effects induced by 1,25(OH)\(_2\)D\(_3\)**

To further confirm the role of the VD/VDR signaling pathway in breast cancer, the VDR inhibitor, calcifediol was used in the following experiments. First, VDR expression was measured by Western blot methods, and the pcDNA3.0 VDR was shown to significantly promote VCR expression in stem-like cells. However, a significant suppression of VDR expression was detected in cells that had been treated with calcifediol (\( P < 0.05 \), Figure 4A). CCK8 assay results showed that cells that highly expressed the VDR were also more sensitive to tamoxifen, and calcifediol could attenuate that trend. We also found that cells with higher levels of VDR expression formed relatively smaller spheroid bodies (\( P < 0.05 \), Figure 4C), and this trend could be reversed by treatment with the VDR inhibitor.

Furthermore, EdU staining results showed that cell viability was significantly decreased (\( P < 0.05 \), Figure 4D), and cell apoptosis rates were increased (\( P < 0.05 \), Figure 4E) when the VDR was overexpressed. However, cell survival was promoted by treatment with calcifediol, as shown by higher cell viability rates and lower rates of apoptosis (\( P < 0.05 \), Figure 4D,E). Further experiments showed that overexpression of the VDR promoted Wnt and β-catenin expression, and their expression could be suppressed by calcifediol treatment.

**Discussion**

CSCs play crucial roles in the initiation, metastasis, and drug resistance of tumors [6–8]. Many CSCs from malignancies have been identified during the past decades, and been reported to mediate tumor metastasis and chemotherapy resistance [9,10]. In our study, we found that when compared with parental MCF-7 cells, MCF-7 stem cells had a higher IC\(_{50}\) value for tamoxifen. Therefore, we became interested in the tamoxifen sensitivity mediated by MCF-7 stem cells.

Previous studies have provided insights into effects of 1,25(OH)\(_2\)D\(_3\), a VDR agonist, and the VDR, and how their interaction helps to regulate cell differentiation, the cell cycle, autophagy, and apoptosis [1,25,26]. Artaza et al. [26] reported that administration of the VDR ligand 1,25D inhibited the proliferation of mesenchymal multipotent cells by arresting the cell cycle at the G0/G1 phase, rather than by inducing apoptosis. They also found that the cells could increase in size without an induction of Wnt-1 expression. Hager et al. [27] reported that administration of 1,25(OH)\(_2\)D\(_3\) to squamous cell head and neck carcinoma cell lines induced G0/G1 cell cycle arrest by promoting VDR-mediated p21 and p27 expression. Genes regulated by 1,25(OH)\(_2\)D\(_3\) not only modulate the cell cycle, but are also involved in apoptosis [1]. In our present study, we demonstrated that administration of 1,25(OH)\(_2\)D\(_3\) to MCF-7 cells promoted G0/G1 cell cycle arrest, and cell apoptosis by inducing expression of the VDR. These results suggest that 1,25(OH)\(_2\)D\(_3\)-induced VDR expression might be responsible for 1,25(OH)\(_2\)D\(_3\)-mediated MCF-7 cell apoptosis.

Given that CSCs are responsible for the initiation, metastasis, and drug resistance of cancers, and activation of the Wnt signaling pathway in CSCs is required for tumorigenesis and metastasis [5–8,12], we sorted MCF-7 stem cells by using fluorescence-activated cell sorting methods and the CD133 antibody to examine VDR expression and activation of Wnt/β-catenin signaling in MCF-7 cells. We first confirmed that the IC\(_{50}\) value of tamoxifen for MCF-7 stem cells was higher than that for the parental MCF-7 cells, suggesting tamoxifen resistance. Next, we found that the levels of VDR expression in CSCs (CD133\(^+\)) were lower than those in the differentiated cells (CD133\(^-\)). As expected, we found that the Wnt/β-catenin signaling pathway was highly activated in MCF-7 stem cells. In contrast, the VDR overexpression-induced inactivation of Wnt/β-catenin signaling produced tamoxifen sensitivity in MCF-7 stem cells. Taken together, these results suggest that the activated Wnt/β-catenin signaling pathway was responsible for the tamoxifen resistance of MCF-7 stem cells.

Persistent activation of the oncogenic Wnt/β-catenin signaling pathway in cancer cells is critical for tumor initiation and metastasis, because it promotes the accumulation of its target genes [5,20]. The 1,25D ligand-activated VDR in colon carcinoma cells competes with a β-catenin binding member (Tcf4) for β-catenin binding [28,29].
**Figure 3. VDR overexpression in CSCs.**

CSCs were transfected with a VDR overexpression plasmid (pcDNA3.0) and incubated with 0.1 μM 1,25(OH)2D3 for 7 days or 2 days. (A) Expression of the VDR protein in transfected cells. (B) The tamoxifen concentration that reduced the numbers of viable transfected CSCs by 50% (IC50). (C) SEM imaging of CSC spheroids. (D, E) EdU and apoptosis flow cytometric analysis, respectively. (F) Expression of Wnt/β-catenin signaling factors in VDR-overexpressing CSCs. GAPDH was used as a reference control in the Western blot analyses. * and ** respectively denote P < 0.05, 0.01 and 0.001 compared with NC.
Figure 4. Effect of calcifediol on CSCs overexpressing the VDR.

(A) Expression of the VDR protein in CSCs was measured by Western blot. (B) The IC50 value of tamoxifen in each group of CSCs. (C) The spheroid formation ability of the CSCs in each group. (D) CSC viability was measured by flow cytometry. (E) Cell apoptosis rates were measured by flow cytometry. (F, G) Expression of Wnt and β-catenin was measured by Western blot methods. *P<0.05 compared with NC; #P<0.05 compared with pc-VDR. ** denotes P < 0.01 compared with NC.
Increasing evidence suggests that vitamin D or a 1,25(OH)2D3 supplement can inhibit tumor growth and inactivate Wnt/β-catenin signaling by promoting the binding of β-catenin to the VDR, thus blocking the transduction of Wnt/β-catenin signaling [30,31]. Increased expression of the VDR or administration of vitamin D and its agonists served to inhibit or negatively regulate Wnt/β-catenin signaling, as well as tumorigenesis and metastasis [29,32,33]. Vitamin D administration also induces the expression of E-cadherin, and thus inhibits EMT progression by modulating the β-catenin/TCF-4 axis, which exerts an opposite effect on the β-catenin signaling pathway, and thereby suppresses tumorigenesis and the metastasis of colon carcinoma cells [28]. In the present study, we demonstrated a negative regulatory relationship between the VDR and Wnt/β-catenin signaling. The administration of 1,25(OH)2D3 to MCF-7 cells and overexpression of the VDR in MCF-7 stem cells induced VDR expression and inhibited MCF-7 cell proliferation and the expression of Wnt and β-catenin proteins. Accordingly, we suggest that these results demonstrate that administration of vitamin D or 1,25(OH)2D3 to MCF-7 cells can inhibit cell proliferation and increase cell sensitivity to tamoxifen by suppressing Wnt/β-catenin signaling.

**Conclusion**

Taken together, we found that administration of 1,25(OH)2D3 to MCF-7 cells arrested the cells at their G0/G1 phase, inhibited cell proliferation, promoted cell apoptosis, and caused DNA damage. Administration of vitamin D activated the VDR, which subsequently inhibited Wnt/β-catenin signaling and thus increased cell sensitivity to tamoxifen. We also demonstrated that the resistance of MCF-7 cells to tamoxifen was mainly mediated by MCF-7 stem cells, and that overexpression of the VDR in stem cells increased tamoxifen sensitivity in MCF-7 stem cells by inhibiting Wnt/β-catenin signaling. Vitamin D supplementation, a stimulation of VDR expression, or the inhibition of Wnt/β-catenin signaling in breast CSCs might be a useful approach for the clinical treatment of breast cancers.

**Competing interests**

The authors declare that there are no competing interests associated with the manuscript.

**Funding**

This research was supported by the Star-up Foundation for Leader of Department in The third People’s Hospital of Shenzhen (grant number 2013SK3189); Scientific Research Fund of Hunan Provincial Education Department [grant number 15B225]; Scientific Research Fund of Hunan Provincial Health and Family Planning Commission [grant number C2017014]; and Hunan Provincial Natural Science Foundation of China [grant number 2018JJ6123].

**Author contribution**

W.Z. and B.D. designed experiment and performed most of the experiments; O.Z., L.O., and W.P. help W.Z. to perform experiments and collect the data; B.D. and W.Z. analyzed the data and interpreted the results; F.Q., Y.W., and S.H. performed the data analysis. W.Z. wrote the manuscript draft, and all authors revised and approved the manuscript before submission.

**Abbreviations**

BD, Becton Dickinson; bFGF, Basic fibroblast growth factor; CCK8, Cell-counting kit-8; CDS, Coding sequences; CSC, cancer stem cells; DMEM, Dulbecco's Modified Eagle Medium; ECL, Enhanced chemiluminescence; EGF, Epidermal growth factor; EMT, Epithelial mesenchymal transition; FITC, Fluorescein isothiocyanate; HRP, Horse radish peroxidase; MCF-7, Michigan Cancer Foundation-7; VDR, vitamin D receptor.

**References**

1. Narvaez, C.J. et al. (2014) The impact of vitamin D in breast cancer: genomics, pathways, metabolism. *Front. Physiol.* 5, 00213, [https://doi.org/10.3389/fphys.2014.00213](https://doi.org/10.3389/fphys.2014.00213)

2. Zheng, Y. et al. (2017) Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt/β-catenin signaling. *Bone Res.* 5, 17023, [https://doi.org/10.1038/boneres.2017.23](https://doi.org/10.1038/boneres.2017.23)

3. Almendro, V. et al. (2014) Genetic and phenotypic diversity in breast tumor metastases. *Cancer Res.* 74, 1338–1348, [https://doi.org/10.1158/0008-5472.CAN-13-2357-T](https://doi.org/10.1158/0008-5472.CAN-13-2357-T)

4. Arnold, K.M. et al. (2015) Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. *Cancer Growth Metastasis* 2015, 1–13

5. Takebe, N. et al. (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. *Nature Rev. Clinical Oncol.* 12, 445–464, [https://doi.org/10.1038/nrclinonc.2015.61](https://doi.org/10.1038/nrclinonc.2015.61)

6. Li, X. et al. (2017) miR-181b-5p mediates TGF-β1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells. *Int. J. Oncol.* 51, 158–168, [https://doi.org/10.3892/ijo.2017.4007](https://doi.org/10.3892/ijo.2017.4007)
7 Piaks, V., Kong, N. and Werb, Z. (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16, 225–238, https://doi.org/10.1016/j.stem.2015.02.015
8 Jaggiuilli, A. and Eikord, E. (2012) Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clinical Dev. Immunol. 2012, 708036, https://doi.org/10.1155/2012/708036
9 Liu, S. et al. (2013) Breast cancer stem cell transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2, 78–91, https://doi.org/10.1016/j.stemcr.2013.11.009
10 Bartucci, M. et al. (2015) TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34, 681, https://doi.org/10.1038/onc.2014.5
11 Todaro, M. et al. (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342–356, https://doi.org/10.1016/j.stem.2014.01.009
12 Takebe, N. et al. (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nature Rev. Clinical Oncol. 1, 97–106, https://doi.org/10.1038/nrclonc.2010.100
13 Génestier, C. and Wicha, M.S. (2007) Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res. Bcr. 9, 109, https://doi.org/10.1186/bcr1741
14 Gong, Y. et al. (2014) Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. Clin. Breast Cancer 14, e81–e88, https://doi.org/10.1016/j.cbc.2013.12.006
15 Ferrermayorga, G. et al. (2016) Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. Gut 66, 1449, https://doi.org/10.1136/gutjnl-2015-310977
16 Bolland, M.J. et al. (2014) The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol. 2, 307–320, https://doi.org/10.1016/S2213-8587(13)70212-2
17 Bolland, M.J. et al. (2011) Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set. Am. J. Clin. Nutr. 94, 1144–1149, https://doi.org/10.3945/ajcn.111.150532
18 Feldman, D. et al. (2014) The role of vitamin D in reducing cancer risk and progression. Nat. Rev. Cancer 14, 342–357, https://doi.org/10.1038/nrc3691
19 Bong, Y.S. et al. (2016) A role for the vitamin D pathway in non-intestinal lesions in genetic and carcinoagenic models of colorectal cancer and in familial adenomatous polyposis. Oncotarget 7, 80508–80520, https://doi.org/10.18632/oncotarget.12768
20 Arentsman, M.D. et al. (2015) Abstract B77: Vitamin D suppresses pancreatic cancer growth through inhibition of autocrine Wnt/β-catenin signaling. Cancer Res. 75, [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR, https://doi.org/10.1158/1538-7445.PANCA2014-B77
21 So, J.Y. and Suh, N. (2015) Targeting cancer stem cells in solid tumors by vitamin D. J. Steroid Biochem. Mol. Biol. 148, 79–85, https://doi.org/10.1016/j.jsbmb.2014.10.007
22 Ójo, D. et al. (2015) Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion. Curr. Med. Chem. 22, 2360, https://doi.org/10.2174/0929867322666150416095744
23 Luo, Y. et al. (2015) Single-cell transcriptome analyses reveal signals to activate dormant neural stem cells. Cell 161, 1175–1186, https://doi.org/10.1016/j.cell.2015.04.001
24 Boo, L. et al. (2016) miRNA transcriptome profiling of spheroid-enriched cells with cancer stem cell properties in human breast MCF-7 cell line. Int. J. Biol. Sci. 12, 427–445, https://doi.org/10.7150/ijbs.12777
25 Wu, S. et al. (2015) Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut 64, 1082–1094, https://doi.org/10.1136/gutjnl-2014-307436
26 Artaza, J.N. et al. (2010) 1,25(OH)2 vitamin D3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cells. J. Steroid Biochem. Mol. Biol. 119, 73–83, https://doi.org/10.1016/j.jsbmb.2010.10.001
27 Hager, G. et al. (2001) 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 121, 103–109, https://doi.org/10.1080/0001648013000066353
28 Palmer, H.G. et al. (2001) Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of α-β<sub>2</sub> -catenin signaling. J. Cell Biol. 154, 369–388, https://doi.org/10.1083/jcb.200102028
29 He, W. et al. (2011) Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J. Am. Society Nephrol. Jasn 22, 90–103, https://doi.org/10.1681/ASN.2009121236
30 Sebo, A., Kahn, M. and Lenz, H.J. (2014) The potential of targeting Wnt/R2-catenin in colon cancer. Expert Opin. Ther. Targets 18, 611–615, https://doi.org/10.1517/14728222.2014.906580
31 Li, J. et al. (2015) Wnt/β-catenin signaling pathway in skin carcinogenesis and therapy. Biomed Res. Int. 2015, 964842
32 Shah, S. et al. (2006) The molecular basis of vitamin D receptor and β-Catenin Crossregulation. Mol. Cell 21, 799–809, https://doi.org/10.1016/j.molcel.2006.01.037
33 Pendás-Franco, N. et al. (2008) Vitamin D and Wnt/β-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res. 28, 2613–2623